Home › PTC Therapeutics Receives Positive Opinion From CHMP For Translarna (ataluren)
 

Keywords :   


PTC Therapeutics Receives Positive Opinion From CHMP For Translarna (ataluren)

2014-06-04 13:02:23| drugdiscoveryonline News Articles

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that following its request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the company's application for a conditional marketing authorization of TranslarnaTM (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older

Tags: positive opinion receives therapeutics

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07High input costs, rising interest rates continue to weigh on farmer sentiment
03.07Sensory analysis shows pork has 111 unique flavor nuances
03.07Hurricane Beryl Graphics
03.07Hurricane Beryl Public Advisory Number 19A
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07'Floodgates open' for legal action against water firms
03.07Atlantic Tropical Weather Outlook
03.07Eastern North Pacific Tropical Weather Outlook
More »